MAPT and Alzheimer disease: Since our group has found passive immunotherapy with tau antibody 43D against tau6-18 could reduce tau and Aβ pathologies, improve cognitive function, and block the propagation of tau pathology templated by AD P-tau in 3xTg-AD mice (Dai et al., 2017, 2018), we modified our SNAP-AD5 vaccine by adding a peptide of tau1-22 and removing the peptide of tau207-227 because of its relative low immunogenicity in our previous study (Song et al., 2024).